- Publisher Correction
- Open Access
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
Experimental Hematology & Oncology volume 11, Article number: 106 (2022)
Correction: Experimental Hematology & Oncology (2022) 11:101 https://doi.org/10.1186/s40164-022-00356-0
In this article  the wrong figure appeared as Fig. 1, The Fig. 1 should have appeared as shown below. 4th affiliation was inadvertently supplied and published, this has been removed. Citation for following references are missing.
The original article has been corrected.
List of Citation and References missing in the article:
Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Zhang L. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of hematology & oncology. 2018 Dec;11(1):1–8.
Merry CR, Forrest ME, Sabers JN, Beard L, Gao XH, Hatzoglou M, et al. DNMT1-associated long non-coding RNAs regulate global gene expression and DNA methylation in colon cancer. Hum Mol Genet. 2015 Nov 1;24(21):6240–53.
Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004 Nov 15;22(22):4632–42.
Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci. 2019 Jan 29;16(3):424–442.
Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 Aug;6(8):827–37.
Giri AK, Aittokallio T. DNMT Inhibitors Increase Methylation in the Cancer Genome. Front Pharmacol. 2019 Apr 24;10:385.
Maouche N, Kishore B, Bhatti Z, Basu S, Karim F, Sundararaman S, et al. Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS One. 2022 Jul 7;17(7):e0270854.
Chen X, Liu X, Zhang Y, Huai W, Zhou Q, Xu S, et al. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages. Cell Mol Immunol. 2020 Jan;17(1):76–84.
Ebine K, Kumar K, Pham TN, Shields MA, Collier KA, Shang M, et al. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. Sci Rep. 2018 Sep 5;8(1):13225.
Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep. 2017 Feb 28;18(9):2162–2174.
Mathsyaraja H, Thies K, Taffany DA, Deighan C, Liu T, Yu L, et al. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene. 2015 Jul;34(28):3651–61.
Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, et al. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Sci Adv. 2021 Feb 10;7(7):eabb3555.
Dai M, Liu M, Yang H, Küçük C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101. https://doi.org/10.1186/s40164-022-00356-0.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Dai, M., Liu, M., Yang, H. et al. Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol 11, 106 (2022). https://doi.org/10.1186/s40164-022-00359-x